• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

口服选择性雌激素受体降解剂（SERD）艾拉司群用于新诊断的雌激素受体阳性、人表皮生长因子受体2阴性早期乳腺癌的术前机会窗研究：EMBER-2研究结果

A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.

作者信息

Neven Patrick, Stahl Nicole, Vidal Maria, Martín Miguel, Kaufman Peter A, Harbeck Nadia, Hunt Kelly K, Carter Stacey, Bidard Francois-Clement, Fasching Peter A, Aftimos Philippe, Wheatley Duncan, Hamilton Erika, Aft Rebecca, Kulkarni Swati, Schmid Peter, Bhave Manali, Ismail-Khan Roohi, Karacsonyi Claudia, Estrem Shawn T, Nguyen Bastien, Ozbek Umut, Yuen Eunice, Rodrik-Outmezguine Vanessa, Ciruelos Eva

机构信息

Leuven Cancer Institute, Universitaire Ziekenhuizen (UZ), Leuven, Belgium.

Helios Kliniken Schwerin, Schwerin, Germany.

出版信息

Clin Cancer Res. 2024 Dec 2;30(23):5304-5313. doi: 10.1158/1078-0432.CCR-24-2113.

DOI:10.1158/1078-0432.CCR-24-2113
PMID:39377773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609621/
Abstract

PURPOSE

Imlunestrant is an oral selective estrogen receptor degrader with favorable safety and preliminary efficacy in patients with advanced breast cancer. Pharmacodynamic (PD) biomarker data can optimize drug dosing; in this study, we present PD data from the EMBER-2 study.

PATIENTS AND METHODS

Postmenopausal women with untreated, operable estrogen receptor (ER)-positive, HER2-negative early breast cancer were randomized to 400 versus 800 mg of imlunestrant daily for ∼2 weeks before surgery. A single arm study tested a daily dose of 200 mg. PD biomarker changes (ER, progesterone receptor, Ki-67 by IHC, and mRNA expression of ER-related genes) were evaluated in paired tumor samples (pre-/posttreatment). Safety and pharmacokinetics were also assessed.

RESULTS

Among evaluable paired samples (n = 75), PD profiles demonstrated consistent ER targeting between 400- and 800-mg doses, with less toxicity at the 400-mg dose. Although inducing the lowest rate of complete cell-cycle arrest, PD and pharmacokinetic results were similar for the 200-mg dose.

CONCLUSIONS

EMBER-2 combined with existing phase I data has identified 400 mg as the optimal imlunestrant dose.

摘要

目的

Imlunestrant是一种口服选择性雌激素受体降解剂，在晚期乳腺癌患者中具有良好的安全性和初步疗效。药效学（PD）生物标志物数据可优化药物剂量；在本研究中，我们展示了EMBER-2研究的PD数据。

患者与方法

未接受治疗、可手术的雌激素受体（ER）阳性、人表皮生长因子受体2（HER2）阴性的绝经后早期乳腺癌女性患者在手术前随机分为每日服用400 mg与800 mg的Imlunestrant，持续约2周。一项单臂研究测试了每日200 mg的剂量。在配对的肿瘤样本（治疗前/后）中评估PD生物标志物变化（通过免疫组化检测ER、孕激素受体、Ki-67，以及ER相关基因的mRNA表达）。同时评估安全性和药代动力学。

结果

在可评估的配对样本（n = 75）中，PD图谱显示400 mg和800 mg剂量之间对ER的靶向作用一致，400 mg剂量的毒性较小。尽管200 mg剂量诱导完全细胞周期停滞的发生率最低，但其PD和药代动力学结果相似。

结论

EMBER-2研究结合现有的I期数据确定400 mg为Imlunestrant的最佳剂量。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4300/11609621/32e192b193df/ccr-24-2113_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4300/11609621/92d080ab19d5/ccr-24-2113_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4300/11609621/ceb98d25194e/ccr-24-2113_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4300/11609621/32e192b193df/ccr-24-2113_f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4300/11609621/92d080ab19d5/ccr-24-2113_f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4300/11609621/ceb98d25194e/ccr-24-2113_f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4300/11609621/32e192b193df/ccr-24-2113_f3.jpg

相似文献

1
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.口服选择性雌激素受体降解剂（SERD）艾拉司群用于新诊断的雌激素受体阳性、人表皮生长因子受体2阴性早期乳腺癌的术前机会窗研究：EMBER-2研究结果
Clin Cancer Res. 2024 Dec 2;30(23):5304-5313. doi: 10.1158/1078-0432.CCR-24-2113.
2
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.依姆鲁司琼，一种口服选择性雌激素受体降解剂，作为单药疗法及与靶向治疗联合用于雌激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌：Ia/Ib期EMBER研究
J Clin Oncol. 2024 Dec 10;42(35):4173-4186. doi: 10.1200/JCO.23.02733. Epub 2024 Sep 6.
3
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.Imlunestrant，一种口服选择性雌激素受体降解剂，作为单一疗法及与阿贝西利联合使用，用于复发性/晚期雌激素受体阳性子宫内膜样子宫内膜癌：1a/1b期EMBER研究结果
Gynecol Oncol. 2024 Dec;191:172-181. doi: 10.1016/j.ygyno.2024.10.006. Epub 2024 Oct 22.
4
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER HER2 Primary Breast Cancer.一项比较新型口服 SERD AZD9496 与氟维司群在新发 ER/HER2 阳性原发性乳腺癌患者中药效学影响的随机、开放标签、术前、机会窗研究。
Clin Cancer Res. 2020 Aug 15;26(16):4242-4249. doi: 10.1158/1078-0432.CCR-19-3387. Epub 2020 Mar 31.
5
A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results.一项在雌激素受体阳性、人表皮生长因子受体 2 阴性的晚期乳腺癌女性中进行的新一代口服选择性雌激素受体降解剂卡米替森（camizestrant）的 I 期剂量递增和扩展试验：SERENA-1 单药治疗结果。
Ann Oncol. 2024 Aug;35(8):707-717. doi: 10.1016/j.annonc.2024.04.012. Epub 2024 May 8.
6
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancer.TBCRC 002：一项 II 期、随机、开放标签临床试验，旨在评估新诊断为 2/3 期激素受体阳性和 HER2 阴性乳腺癌的绝经后女性中，术前使用来曲唑联合或不联合贝伐珠单抗的疗效。
Breast Cancer Res. 2020 Feb 18;22(1):22. doi: 10.1186/s13058-020-01258-x.
7
Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer.依姆鲁司他是一种口服、可穿透血脑屏障的选择性雌激素受体降解剂，在ESR1野生型和突变型乳腺癌中具有强大的抗肿瘤活性。
Cancer Res. 2025 Feb 17;85(4):777-790. doi: 10.1158/0008-5472.CAN-24-2608.
8
Elacestrant in Women with Estrogen Receptor-Positive and HER2-Negative Early Breast Cancer: Results from the Preoperative Window-of-Opportunity ELIPSE Trial.Elacestrant用于雌激素受体阳性且人表皮生长因子受体2阴性的早期乳腺癌女性患者：术前机会窗ELIPSE试验结果
Clin Cancer Res. 2025 Apr 1;31(7):1223-1232. doi: 10.1158/1078-0432.CCR-24-2460.
9
heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer.heredERA 乳腺癌：一项 III 期、随机、开放性研究，评估 giredestrant 联合曲妥珠单抗和帕妥珠单抗固定剂量组合用于皮下注射治疗既往未经治疗的 HER2 阳性、雌激素受体阳性局部晚期或转移性乳腺癌患者的疗效和安全性。
BMC Cancer. 2024 May 24;24(1):641. doi: 10.1186/s12885-024-12179-9.
10
The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.在绝经后激素受体阳性人表皮生长因子受体 2 阴性（HR+/HER2-）的晚期/转移性乳腺癌女性中，口服选择性雌激素受体降解剂 GDC-0810（ARN-810）。
Breast Cancer Res Treat. 2023 Jan;197(2):319-331. doi: 10.1007/s10549-022-06797-9. Epub 2022 Nov 19.

引用本文的文献

1
Extended adjuvant endocrine therapy in early breast cancer: finding the individual balance.早期乳腺癌的延长辅助内分泌治疗：寻求个体化平衡
ESMO Open. 2025 May;10(5):105057. doi: 10.1016/j.esmoop.2025.105057. Epub 2025 Apr 24.
2
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.依姆鲁司琼，一种口服选择性雌激素受体降解剂，作为单药疗法及与靶向治疗联合用于雌激素受体阳性、人表皮生长因子受体2阴性的晚期乳腺癌：Ia/Ib期EMBER研究
J Clin Oncol. 2024 Dec 10;42(35):4173-4186. doi: 10.1200/JCO.23.02733. Epub 2024 Sep 6.

本文引用的文献

1
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.早期乳腺癌：ESMO 诊断、治疗及随访临床实践指南
Ann Oncol. 2024 Feb;35(2):159-182. doi: 10.1016/j.annonc.2023.11.016. Epub 2023 Dec 13.
2
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer.AMEERA-4 研究：阿美纳曲唑对比来曲唑用于早期乳腺癌的随机、术前机会窗研究。
Breast Cancer Res. 2023 Nov 10;25(1):141. doi: 10.1186/s13058-023-01740-2.
3
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study.
在雌激素受体阳性、HER2 阴性的早期乳腺癌患者中，新辅助帕博西尼联合吉瑞替尼或阿那曲唑（coopERA 乳腺癌）：一项开放标签、随机、对照、Ⅱ期研究。
Lancet Oncol. 2023 Sep;24(9):1029-1041. doi: 10.1016/S1470-2045(23)00268-1.
4
Molecular Biomarker Expression in Window of Opportunity Studies for Oestrogen Receptor Positive Breast Cancer-A Systematic Review of the Literature.雌激素受体阳性乳腺癌机会性研究中的分子生物标志物表达——文献系统综述
Cancers (Basel). 2022 Oct 14;14(20):5027. doi: 10.3390/cancers14205027.
5
Improving Dose-Optimization Processes Used in Oncology Drug Development to Minimize Toxicity and Maximize Benefit to Patients.改善肿瘤药物开发中使用的剂量优化流程，以最大限度地降低毒性并使患者受益。
J Clin Oncol. 2022 Oct 20;40(30):3489-3500. doi: 10.1200/JCO.22.00371. Epub 2022 Sep 12.
6
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.Elacestrant（口服选择性雌激素受体降解剂）对比标准内分泌治疗用于雌激素受体阳性、人表皮生长因子受体 2 阴性的晚期乳腺癌：来自随机 III 期 EMERALD 试验的结果。
J Clin Oncol. 2022 Oct 1;40(28):3246-3256. doi: 10.1200/JCO.22.00338. Epub 2022 May 18.
7
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update.激素受体阳性、人表皮生长因子受体 2 阴性转移性乳腺癌的内分泌治疗和靶向治疗：ASCO 指南更新。
J Clin Oncol. 2021 Dec 10;39(35):3959-3977. doi: 10.1200/JCO.21.01392. Epub 2021 Jul 29.
8
Effects of Adjuvant Endocrine Therapy Adherence and Radiation on Recurrence and Survival Among Older Women with Early-Stage Breast Cancer.辅助内分泌治疗依从性和放疗对老年早期乳腺癌患者复发和生存的影响。
Ann Surg Oncol. 2021 Nov;28(12):7395-7403. doi: 10.1245/s10434-021-10064-4. Epub 2021 May 12.
9
Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.在晚期激素受体阳性乳腺癌中，氟维司群与依西美坦的突变和总体生存：SOFEA 和 EFECT 三期临床试验的联合分析。
Clin Cancer Res. 2020 Oct 1;26(19):5172-5177. doi: 10.1158/1078-0432.CCR-20-0224. Epub 2020 Jun 16.
10
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER HER2 Primary Breast Cancer.一项比较新型口服 SERD AZD9496 与氟维司群在新发 ER/HER2 阳性原发性乳腺癌患者中药效学影响的随机、开放标签、术前、机会窗研究。
Clin Cancer Res. 2020 Aug 15;26(16):4242-4249. doi: 10.1158/1078-0432.CCR-19-3387. Epub 2020 Mar 31.